Valued at USD 8.63 billion in 2024, the pruritus therapeutics market is projected to reach USD 8.97 billion in 2025 and USD 12.61 billion by 2034, growing at a CAGR of 5.50% during the forecast period 2025–2034. Major players include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb, Cara Therapeutics, GSK plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical...